Review Articles

2018  |  Vol: 3(5)  |  Issue: 5 (September- October) |
Perspectives on regulatory actions of liver X receptors (LXR) in obesity

Yash Prashar, Manisha Singha, Imroze Singh  

Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, Distt. S.B.S Nagar, Punjab, India

*Address for Corresponding Author:

Yash Prashar

Department of Pharmacology

Rayat Institute of Pharmacy, Railmajra, Distt. S.B.S Nagar, Punjab, India


Liver X receptors are cholesterol sensing receptors and are the members of nuclear receptor superfamily. LXRs are generally present in two isoforms LXR α and LXR β. Initially LXRs were isolated as Orphan receptors form a rat cDNA libraray from oligonucleotide probe. In this review we focus on regulatory actions of LXR in obesity. LXRs directly act on various target genes like ABCA1, ABCG1, ABCG8, GLUT4, and various other rate limiting enzymes like PEPCK, G6P, F6P and thus play a crucial role in the therapeutics of obesity. LXR potentially interferes with obesity by different signaling pathways. The first is through ABC genes by promoting elimination of excess body cholesterol through lipid removal pathway from cholesterol loaded macrophages and intestinal lumen. The second is through by the up-regulation of GLUT4 expression by increasing glucose uptake by peripheral tissues and the third approach is through the inhibitory action on rate limiting enzymes PCPCK, G6P, F6P that ultimately suppress hepatic glucose production. These physiological roles of LXR indicate that it is an interesting potential target for drug treatment of obesity

Keywords: liver X receptors, obesity, ABC transporters, GLUT4, rate limiting enzymes (PEPCK, G6P, F6P)


Liver X receptors (LXRs) belongs to the superfamily of nuclear receptors and are ligand activated transcription factor that generally activated by the oxidized products of cholesterol (Oxysterols) (Apfel et al., 1994; Janowski et al., 1996, 1999). LXRs are central regulators of cholesterol, free fatty acids, and glucose metabolism. LXRs act as cholesterol sensors: when the concentration of cholesterol increases, as a result of increasing oxidized product of cholesterol the LXRs activates transcription genes that protect cell from cholesterol overload (Zhao et al., 2009).

Initially LXRs were isolated as orphan receptors (i.e receptors with no known physiological effect) from a rat liver c DNA library with the help of oligonucleotide probes (Apfel et al., 1994; Laudet et al., 2002). Currently too LXRs are isolated in the same manner using oligonucleotide probes because  of various advantages like high specificity, resistance to other RNAses, instant availability of deoxynucleotides and better economic availability (Kreil et al., 2006).

The LXR molecules have four main functional domains in its structure: (1) An amino-terminal ligand-independent activation function domain (AF-1), which may trigger transcription when the ligand is not available on site; (2) A DNA-binding domain (DBD) containing two zinc fingers; (3) A hydrophobic ligand-binding domain (LBD) required for the formation of receptor diamers and ligand binding; and (4) a carboxy-terminal ligand-dependent transactivation sequence (activation function-2 (AF-2) domain) that activate transcriptional response through ligand binding (Rechavi et al., 2003).

In mammals Liver X receptors generally exist in two isoforms  LXR α and LXR β that form obligate heterodimer with retinoid X receptors (RXR) (Edward et al., 2002). LXR α generally exists in three forms LXRα1, LXRα 2, LXRα 3 and  LXR β exist in only one form (Chen et al., 2005; Repa et al., 2002). LXRs are closely related to PPARs, FXR, RXR, VDR receptors (Bettowrki et al., 2008). Till now no other new LXR isoform have been reported.

The chief function of LXRs is to maintain cellular cholesterol homeostasis and glucose metabolism, but in addition to that LXRs also modulate immune responses in mammals by regulating gene expression in macrophages that turn out as a therapeutic target for treatment of many chronic inflammatory disorders (Gonzalez et al., 2010). Recent studies have revealed that LXR is a potential therapeutic agents in the treatment of atherosclerosis by adjusting metabolic and inflammatory gene expression (Millatt et al., 2003; Geyeregger et al., 2006).  Activation of liver X receptors inhibit hepatic gluconeogenesis and lowers blood glucose level thus beneficial in the treatment of diabetes mellitus (Geyeregger et al., 2006).

Currently it has been observed that LXR activation in animal models suggest to have crucial role in the prophylaxis of common metabolic disorders, including hyperlipidemia, atherosclerosis and diabetes and obesity (Quinet et al., 2009; Nordstrom et al., 2005; Kase et al., 2007). In rodents, treatment with different LXR agonists leads to reduction in serum and hepatic cholesterol levels (Alberti et al., 2001).

In our present review we are focusing on the role on liver X receptors in obesity. Obesity is a public health complication that has elevated concern worldwide. (Korach-Andre et al., 2011) showed that both liver X receptors isoforms i.e.  LXR α and LXR β increase activity of brown adipose tissue thus increase LXR mediated energy expenditure and thus proved to be a potential target for the treatment of obesity. LXR activation by GW3965 improved glucose tolerance in a mouse model of diet-induced obesity by up regulation of GLUT4 receptors that are direct target genes for liver X receptors (Laffitte et al., 2003). In another study it was revealed that basal glucose uptake was also enhanced after activation of LXR by T0901317 (a potent LXR agonist) in 3T3-L1 cells and in vitro differentiated human adipocytes (Ross et al., 2002).

Types of liver X receptor

Liver X receptors generally exists in two isoforms:

Liver X receptors α: LXR α is a isoform of LXR receptor that is encoded by NR1H3 gene that is generally located on chromosome 11 (Miyata et al., 1996; Willy et al., 1995). LXR α generally exists in three forms LXRα1, LXRα 2, LXRα 3, in which LXRα1 is the most active and generously expressed by all almost tissues like spleen, liver, adipose tissue, intestine, kidney and lungs (Chen  et al., 2005; Repa et al., 2002), LXRα 2 mainly expressed in human testies and cancer cell lines, and LXRα 3 is produced  via an alternative recognition of a 30-splice site in exon 6  and is expressed by human lung, thyroid gland, spleen and cancer cell lines (Laurencikiene et al., 2012). The expression of human LXRα is down regulated by a microRNA has-miR-613 that is known to transcriptionally activate LXRα by SREBP-1c (sterol regulatory element binding proteins) (Ou et al., 2011), the upregulation of LXR α is regulated by the activation of LXRE (LXR response elements) (Chen et al., 2009).

Liver X receptors β: LXR β is another isoform of LXR receptors encoded by NR1H1 gene that is generally located on chromosome 19 (Repa et al., 2002). Isoform LXR β (NR1H2) not abundantly expressed by all tissues (Repa et al., 2002) but LXR β is dominantly expressed by skeletal muscles that regulate lipogenesis and cholesterol efflux (Hessvik et al., 2010). Courtaut et al. (2015) showed that LXR β receptors are predominantly expressed in colon cancer cells but not in normal colon epithelial cells. Down regulation of Liver X receptors in neuronal micro columns and malformed cells also participate in the prophylaxis of FCD (Focal cortical dysplasia).

Table 1. Difference between both isoforms of liver X receptors

S. No.





Encoded gene

NR1H3 gene (lies on chromosome 11)

NR1H1 gene (lies on chromosome 19)



Ubiquitously in all tissues like spleen, liver, adipose tissue, intestine, kidney, testies and lungs.

Less expressed by all tissues but dominantly expressed by skeletal muscles and colon cancer cell lines.



Expressed through LXRE, SREBP and other essential cholesterol elements

Only expressed through LXRE.

Liver X receptors agonists and antagonists

The LXR agonists binds to Liver X receptors and thus activate it to produce certain biological responses where as LXR antagonists deactivates the Liver X receptors and thus inhibit the biological response driven by LXRs.

LXR agonists: Various natural and synthetic agonist analogues are there for initiating the biological response of LXRs. These are given in table 2.

Table 2. Various LXR agonists used as therapeutic drugs in various diseases

S. No.

LXR agonists

Type of agonists





25-epoxycholestrol, 24 (s) hydroxyl cholesterol, 27-hydroxycolestrol and cholestenoic acid

Natural Ligands

Cholesterol metabolism

Glucose metabolism

Bile acid synthesis

Treatment of various metabolic disorders

Lehmann  et al., 1997; Alberti et al., 2001; Huang  et al., 2014



Selective agonists

Treatment of obesity, diabetes, atherosclerosis and inflammatory disorders.

Laffittee  2003; Joseph  et al., 2003



Selective agonists

Treatment of atherosclerosis, obesity, prostate cancer, alzheimer and breast cancer.

Alberti et al., 2001; temml et al., 2014; Chuu et al., 2006; Im  et al., 2011


22 (R) hydroxyl cholesterol

Partial agonist

Treatment of prostate, breast cancer and various other metabolic disorders like obesity.

Chuu et al., 2006; Im  et al., 2011



Selective agonist

Potassium channel blocker

Bramlett  et al., 2003



Selective agonist

Lipid metabolism

Vainio  et al., 2005; Yang et al., 2006



Selective agonist

Cholesterol regulation

Menke  et al., 2002



Selective agonist

Inducing the expression of LXRα, PPARα, ApoE,


Taylor et al., 2014



Selective agoists

Promoting CYP7A1 and ABCG5/ABCG8

expression through the PPARγ/LXRα pathway

Byun et al., 2014



Selective agonist

Promoting HO-1 and LXRβ expression through the AMPK-ATF1 pathway

Wan et al., 2013

LXR antagonists: Various substances inhibit the response of liver X receptors, few of them are given in table 3.

Table 3. Various LXR antagonists used as therapeutic drugs in various diseases

S. No.

LXR Antagonists

Type of antagonist





Selective LXR antagonist

Used in cell biology study as chemical probe. Treatment of inflammatory and autoimmune diseases

 Solt et al., 2012; Zuercher et al., 2010;  Griffett et al., 2016



Selective LXR antagonist

Treatment of fatty liver (non-alcoholic).

Decrease lipogenic gene expression.

 Sim et al., 2015


22 (S) hydroxyl cholesterol

Partial and dose dependent LXR antagonist

Treatment of skin fibroblasts.

Gondcaille  et al., 2014



Selective LXR antagonist

Treatment of obesity and other metabolic disorders.

 Sheng et al., 2012



pyrophosphate (GGPP)

Non selective LXR Antagonist

Down regulate mevalonate metabolism.

Beltowski, 2008


Polyunsaturated fatty acids (PUFAs)

Competitive LXR antagonist

Downregulate SREBP-1c

Yoshikawa  et al., 2002

Transcriptional regulation of genes by LXRs

Various biological substances such as oxysterols, bile acids etc act as signaling molecule for the activation of various types of nuclear receptors (Janowski et al., 1996). Nuclear receptors are generally ligand activated transcription factors that regulate transcription of various genes and thus involved in various biological processes ( Li et al., 2013). In the transcriptional regulation of liver X receptors, target genes get activated when LXR binds to some specific DNA sequences associated with those particular target genes (Zhao et al., 2009). LXRs binds to the isoforms of retinoid X receptors (RXR) i.e RXRa, RXRb and RXRc and thus in combination form constrain heterodiamers with each other (Makishima, 2006). LXRs generally regulate gene experssion via the activation of LXR response elements (LXREs) in the promotor region of DNA of target gene (Verreault et al., 2006). The constrain heterodiamer of LXR-RXR then activated LXR response elements (LXREs) that consist of two direct repeats AGGTCA spearated by four nucleotides (Li et al., 2013; Chawla et al., 2001). Through this mechanism LXRs known to regulate the various target genes such as polypeptide A3 and UDP Glucuronosyltransferase (Verreault et al., 2006), phospholipid transfer protein (Mak et al., 2002) etc.

Liver X receptors also known to regulate the transcriptional activity of various glucocorticoid receptors (Nader et al., 2012). Glucorticoids generally increases the transcription rate of glucose-6-phosphatase and its various enzymes and thus mediate gluconeogenesis and glycogenolysis (Lin et al., 1998). LXRs generally regulates the cholesterol turnover and the hepatic glucose metabolism by binding with various cholesterol metabolites which further heterodiamerise with Retinoid  X Receptors thus leads to decrease the expression of glucose-6-phosphatase (Nader et al., 2012). LXRs also known to inhibit dexamethasone-stimulated GR transcriptional activity in HCT116 cells (Cell line human colon carcinoma) (Kino et al., 2007). But in case of HepG2cells LXRs regulate dexamethasone stimulated mRNA expression of endogenous glucocorticoid-responsive genes (Nader et al., 2012). LXRs also carry out the transcriptional regulation of Farnesyl pyrophosphate synthase (FPPS) that is a LXR target gene in astrocytes and neurons and play a major role in regulating cholesterol synthesis in the brain  (Fukuchi et al., 2003). In addition to that Hepatocyte Nuclear Factor 4 α (HNF-4α) controls transcriptional regulation of  LXR α (a isoform of LXR) that plays a major role in cholesterol homeostasis, overexpression of HNF-4α in HEK 293T cells increased the expression of all LXRα thus alter cholesterol homeostasis.

LXR mediated ATP transport in cholesterol efflux

 ATP binding cassette (ABC) transporters plays pivotal role in enhancing acceptor’s cholesterol efflux through liver X receptors, ABCA1, ABCG1, ABCG4, ABCG5, ABCG8 of ABC transporter family are target genes of LXRs ( Zhu et al., 2012). ATP binding cassette transporters are also called cholesterol efflux regulatory protein (CERP) encoded by various target genes like ABCA1, ABCG4, ABCG5, ABCG8 (Luciani et al., 1999; Zhu et al., 2012) which are major regulator for cholesterol homeostasis (Luciani et al., 1999). ABCA1 protein is essential for the efflux of extra cellular cholesterol to Apo Receptors such Apo 1 (the first step in cholesterol transport) (Hozoji Inada et al., 2011). Transcriptional level of LXR receptor regulate ABCA1 mediated cholesterol efflux (Donkin  et al., 2010). ABC transporter contain 4 domains (a) two membrane spaning transmembrane domains (b) two nucleotide binding domains, hydrolysis of ATP in nuclear binding domain provide energy for transport of substrate (Vaisman  et al., 2001).  Laun et al. (1999) established that ABCA1 play crucial role in cellular apolipoprotein mediated lipid removal pathway.

ABCA1 is an inherent membrane transporter that play a crucial role in generation of high density lipoproteins (HDL) (Bodzioch et al., 1999). ABCA1 mediate post transational regulation as well as transcriptional response to maintain cholesterol homeostasis (Zhu et al., 2012). Along with that ABCA1 also play remarkable role in removing lipid from cholesterol loaded macrophages (Vaisman et al., 2001), it tremendously occurs in inhabitant macropahges where it play important role in cholesterol transport (Schaefer et al., 1981; Meurs et al., 2008). Elevation of cholesterol loaded macrophages inside the body serves as a key for the activation of LXR/RXR heterodimer (Venkateswaran  et al., 2000;  Vaughan et al., 2005) which further bind to the promoter region of ABCA1 and activates ABCA1 transcription (Costet et al., 2000; Schwartz  et al., 2000). Macrophages cholesterol then get oxidized and get converted to oxysterol that are prime activator of LXR (Vaughan et al., 2005). LXR-RXR heterodimer act as sensor for cellular cholesterol that further functions as a mediator for cholesterol efflux by initiating the expression of cholesterol shuffling vehicle i.e. ABCA1 and Apo A-1, abnormal increased expression of these vehicles leads to cholesterol dys-homeostasis (Akran  et al., 2010).

At cellular level activation of LXRs initialize the response of ABCA1 and ABCG1 genes and thus transport cellular cholesterol to Apo A-1 (produced by liver), Apo A-1 accept free cholesterol and phospholipids from macrophages that further form HDL particles furthermore those nascent HDL get mature into spherical HDL with the help of cholesterol esterifying enzyme (lysolecithin cholesterol acyl transferase) and cholesterol esters. Mature HDL then move to liver by SR-B1 (Scavenger receptor class B type 1) to other lipoprotein by CETP (Cholesteryl ester transport protein) (Oram and Heinecke et al.,  2005; Shah  et al., 2001; Rye   et al., 2004;  Zhu et al., 2012). HDL then moves to liver and cause increase in LXR dependent 7-α-hydroxylase expression result in increase bile acid synthesis and elimination. With increase in the biliary excretion there is increase in intestinal uptake of cholesterol by LXR mediation that eliminate excess body sterol by ABC sterol transport (Repa et al., 2002; Berge et al., 2005). After endocytosis low density lipoproteins get moved to hepatocytes by LDLR (Low density lipoprotein receptors), then LDL get hydrolysed to free cholesterol, from where it either get recycled in ABCA1 pathway which further secreted in bile acid or get reorganized into lipoproteins and is secreted to circulation (Oram and Heinecke, 2002).

In contrast ABCG1 carry out the mediation of cholesterol efflux to HDL particles but not through Apos (Kennedy et al., 2005). Interestingly, the loss of ABCA1 and ABCG1 in mice model results in a synergistic increase in tissue lipid accumulation, induction of LXR agonist help to manage cellular cholesterol overload (Out et al., 2008; Yvan-Charvet et al., 2007; Aye et al., 2010).

Obesity is corresponding to the accumulation of both cholesterol and TGs (triglycerides) in adipose tissues that generally occurs due to impairment in the expression of ABC transporters (Yu B-L et al., 2010; Dugail et al., 2003). Activation of LXR up regulate ABCA1, ABCG1 and ABCG8 expression and thus play potential role in the therapeutics of obesity and related syndrome by facilitating ABCA1 mediated efflux of cholesterol and phospholipids to lipid-poor lipoproteins (e.g., apoA-I), and its induction may contribute to the increase in plasma HDL levels seen with LXR ligand treatment (Repa et al., 2000).

Figure 1. Cholesterol transport by ABCA1 and ABCG1 mediated by liver X receptors


Two other member of ABC transporters family are ABCG5 and ABCG8 genes encoded by proteins sterolin 1 and sterolin 2 respectively, which play a major role in regulation of sterol or cholestrol absorption and excretion (Lee  et al., 2001). Both of them are predominately expressed in enterocytes and is a selective tool for sterol excretion by the liver into bile (Patel et al., 1998). Berge et al., showed that ABCA1, ABCG5, ABCG8 are direct genes for the activation of LXR/RXR heterodiamer in liver and intestine. In in situ hybridization LXR agonist elevate the level of ABCA1, G4 and G8 in hepatocytes and enterocytes that initiate transcriptional m RNA response of LXR-RXR heterodiamer in intracellular sterol sensor, that further transport cholesterol from the inner leaflet of canalicular membrane, followed by ATP binding and hydrolysis that leads to modification in the appearance of cholesterol molecule and thus flipping toward the outer leaflet of canalicular membrane (Wittenbury  et al., 2002; Yu et al., 2014). This whole process further leads to decrease in cholesterol absorption in intestinal lumen and leads to cholesterol efflux through RCT (Reverse cholesterol transport) (Graf et al., 2002; Yu et al., 2014). LXRα is considered  as the one of the crucial regulator of ABCG5 and ABCG8 mRNA expression, in addition to that the LXR agonist T0901317 markedly increase the expression of  ABCG5 and ABCG8 in the small intestine and liver of wild type but not LXRα knockout mice (Gonzalez-Granillo et al., 2012;  Veen et al., 2007).

Figure 2. LXR mediated cholesterol transport in intestinal lumen.



LXR mediated GLUTs (GLUT4) in glucose transport, storage and utilization

Glucose transporters are immense category of membrane obligated proteins that are found in all mammalian tissues and promote transport of glucose across plasma membrane (Hruz et al., 2001). Among all categories of GLU transporters GLUT1 and GLUT4 impersonate crucial part in glucose transport and thus sustain glucose homeostasis (Laffitte et al., 2003). GLUT1 is ubiquitously found in erythrocytes and endothelial barrier cells of central nervous system, where as GLUT2 is widely exhibited by liver cells, pancreatic beta cells and kidneys (specifically renal tubular cells),  GLUT4 is extensively expressed by adipose tissues and striated muscles (skeletal and cardiac muscles) (Thorens  et al., 2010). But enormously defect in the signaling pathway of GLUT4 in adipose tissue plays extended role in obesity and related syndrome Favaretto et al., 2012). Glut 4 receptors have moderate Km values that means they have moderate infinity for glucose (Olson et al., 2012). GLUT4 generally carry out insulin dependent glucose uptake (Ebeling et al., 1998). Under the condition when insulin level is low, GLUT4 primarily reside in intracellular membrane. When there is rise in circulating insulin levels after ingestion of a carbohydrate containing meal, intracellular GLUT4 redistribute to the plasma membrane, thus initiate glucose uptake and metabolism in these tissues and preventing rapid elevations in blood glucose level (Kahn, 1996).

Glucose transporters such as GLUT4 are the immediate recipient (or direct target) by liver X receptors in adipose tissue and skeletal muscles (Laffitte et al., 2003). LXR able to transmit ligand activated transcription of GLUT4 genes and perform important role in essential or basal regulation of GLUT4 in adipose tissues and skeletal muscles (Laurencikiene et al.,2012; Kase  et al 2005). LXRE (Liver X receptor elements) are located on GLUT 4 promoter region and are positive regulators of GLUT4 (Dalen et al, 2000). Certain levels of glucose or cholesterol in blood causes immediate activation of LXRs. LXR then leads to generation the of LXR-RXR heterodiamer, which further act on GLUT4 receptors and perform cascade of various events (Kase  et al., 2005;  Dalen et al., 2003). Liver X receptor elements directly act on GLUT4 promoter region in adipose tissues and skeletal muscles, thus cause insulin dependent glucose flux (Dalen et al., 2003). In skeletal muscles LXR stimulation cause increase in uptake of glucose and fatty acid, increase storage of fatty acids and increase glucose and fatty acid oxidation, where as in adipose tissue there is increase in uptake of glucose and aid in storage of fatty acids (Steffensen et al., 2006;  Olson et al., 2012).

More precisely in brown and white adipose tissues it is most commonly expressed by LXRα and very less by LXRβ receptors. LXR α causes up regulation of GLUT4 gene and thus increase its expression in adipose tissue that leads to increase in glucose uptake and more fat stored as neutral fat.  LXRs in adipose tissues causes rise in triglyceride (neutral fat) accumulation by direct inducement of lipogenic genes like SREBP-1c and FAs and also increase substrate availability for triglyceride synthesis. In brown adipose tissues GLUT4 causes increase in glucose uptake by tissues, decrease in lipogenesis, decrease in lipid oxidation and increase in lipolysis, where as in white adipose tissues it causes rapid increase in lipid oxidation, increase in adipocyte differentiation, increase in glucose uptake, increase in reverse cholesterol transport and lipogenesis (Laurencikiene et al., 2012).

This approach of mediation of GLUT4 by liver x receptors is proved to be a important approach for the treatment of obesity. Evidences showed that altered expression of GLUT4 in the skeletal muscles leads to obesity (Pederson et al., 1990). Up regulation of GLUT4 with the help of liver X receptors increase peripheral uptake of glucose that serve as a potential approach for the treatment of obesity (Dalen et al., 2003). In contrast, Laffitte et al. (2001) found that Glut4, was upregulated by GW3965 (a selective LXR agonist) in 3T3-L1 cells in vitro and in murine adipose tissue, GLUT4 activation through LXR lowered blood glucose, improved glucose tolerance and upregulated the Glut4 expression in adipose tissue of obese mice (ob/ob mice or diet-induced obese mice), but not in that from lean mice and thus helpful in the treatment of obesity (Laffittee et al., 2003; Grefhorst et al., 2005).

Figure 3. LXR mediated increase glucose uptake by GLUT4 receptors


Rate limiting enzymes mediated by liver X receptors

Phosphenol pyruvate carboxykinase (PEPCK), Glucose-6-phosphate (G6P), fructose 6 phosphate (F6P) these all are the rate limiting enzymes in Embden Meyerhof Parnas Pathway ( Desantis et al., 1988; Holyoak  et al., 2006). G6P and F6P are the direct enzymes involved in EMP (glycolysis) where as PEPCK act as juncture between kreb cycle and glycolysis, PEPCK generally involve in removal of carboxyl group (decarboxylation) and release carbon dioxide (Holyoak  et al., 2006; Jia  et al., 2010). Liver play plethoric role in body functioning, it is generally involve in multiple processes such as glycogen storage, production of bile acid, regulation of blood glucose, lipid metabolism, energy metabolism and detoxification (Postic  et al., 2004). During fasting liver sustain continuous supply of glucose to body by hepatic gluconeogenesis along with that in post prandial state (i.e after meal time) it enhance uptake of hepatic glucose that further promote production of glycogen and increase the process of lipogenesis. Any malfunctioning in the regulation of lipid and hepatic carbohydrate metabolism leads to cause metabolic disorders (Fronzo et al., 1992; Rizza, 2010).

Stulnig et al. (2002) was first to demonstrate that LXR activation resulted in manifestation of downregulation of the key regulating genes in the process of gluconeogenesis in the liver of wild type mice, further more LXR agonist improve the diabetic and obese condition by increasing hepatic glyconeogenesis. Franckhauser et al. (2002) showed that over expression of PEPCK in adipose tissue due to increased fatty acid re-estrification leads to obesity but treatment with LXRs show decrease in this process. In murine model of diet induced obesity, a synthetic LXR agonist i.e GW3965 improve glucose tolerance leads to down regulation of PEPCK, G6P that further stimulate hepatic utilization, bound hepatic glucose output and ameliorate pheripheral glucose uptake (Laffitte et al., 2003). Various experiments showed that synthetic LXR agonists like T0901317 and GW3965 noticeably reduced hepatic glucose output in both ZDF and high-fat fed rats respectively that proved to be a noticeable approach in the treatment of obesity (Cao et al., 2003; Commerford et al., 2007).

Another possible mechanism include the suppression of glucocorticoid signaling, T0901317 was manifested to reduce the expression of glucocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 1 (the enzyme mediating synthesis of active corticosterone in liver  in wild type and db/db mice (Liu  et al., 2006; Stulning  et al., 2002; Gremper  et al., 2005). Since LXR has been found to supress 11β-HSD1 expression that is a key enzyme in conversion of inactive corticosteroids to active corticosteroids (Stulnig et al., 2002). The effects of suppressed glucocorticoid productivity may also help to decrease in hepatic gluconeogenesis. In the LXR-mediated lipogenic effects, LXRα more predominantly showed LXR-mediated effects on glucose metabolism rather than LXR β (Commerford et al., 2007).

Figure 4. Rate limiting enzymes mediated by liver X receptors




LXRs are the traditional lipogenic factors in various tissues including adipose tissue, skeletal muscles, liver, intestine where they assist the conversion of cholesterol to bile acid, increase reverse cholesterol transport and promote excretion of cholesterol from body. In addition to that LXRs also are the important mediator for the insulin dependent glucose transport with the help of GLUT receptors. Thus, activation of liver X receptors has been shown to be anti-obesity, improve glucose uptake by peripheral tissues, remove accumulated lipids from body and inhibit the rate of hepatic glucose production. This makes LXRs an interesting approach in obesity animal models. However both LXRα and LXRβ have separate roles but both seems to be a major target in the treatment of obesity.

Future perspective

The field of LXRs signaling is developing rapidly. New and rousing biological functions of LXRs are observed consistently. Recent studies suggest the role of Liver X receptors in atherosclerosis, diabetes, inflammatory disorders, neurological disorders and obesity. LXRs are the important regulators of the cholesterol metabolism, glucose metabolism, and bile acid synthesis (Zhao et al., 2009; Laffitte et al., 2003). LXRs act through various target genes like ABC genes, GLUTs, PPARs, ApoE, CETP, FAS, SREPB, LPL (Edwards et al., 2002). These findings suggest that LXR participate in regulatory network of all metabolic disorders. LXRs seem to be involved in energy consumption, thermogenesis, control of adipokine production, insulin sensitivity and tolerance to glucose. The role of LXR in obesity is diet dependent but play a crucial role in its treatment. Importantly, the advantageous effects of LXRs on blood glucose levels and RCT (reverse cholesterol transport) towards the unwanted effects on increased lipogenesis must be addressed properly, more especially in mammals for successful pharmaceutical intervention. The next decade of research will most probably focus on these issues and the development of tissue LXR-specific drugs that are challenges for the pharmaceutical industry. The combined work of academic institutions and pharmaceutical industries might well produce the analogues that more specifically work through mediation of liver X receptors and thus will treat intervention of LXR signaling to combat the worldwide increase in diseases caused by improper regulation of lipid, cholesterol and glucose metabolism, including obesity that is a lead cause of other metabolic disorder.

Authors Contribution

Yash Prashar: Conceived idea of the study, participated in its design, coordinated and helped to draft the manuscript. Also, performed statistical analysis

Manisha Singha: Performed laboratory work and participated in the sequence alignment and drafted the manuscript.

Imroze Singh: Performed laboratory work and participated in the sequence alignment and drafted the manuscript.

Conflicts of interest: Not declared.


Olson AL. 2012. Regulation of GLUT4 and insulin dependent glucose flux”.ISRN Molecular Biology., Hindawi, 12, ID856987,(2012)

Alberti S, Steffensen KR, Gustafsson J-A.  2000. Structural characterisation of the mouse nuclear oxysterol receptor genes LXR and LXR. Gene 243(1–2):93–103.

Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. 1994. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Molecular and Cellular Biology 14(10):7025–35.

Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustafsson JA. 2001. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. Journal of Clinical Investigation 107(5):565–73.

Aye IL, Waddell BJ, Mark PJ, Keelan JA. 2010. Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity. Biochimica et Biophysica Acta 1801:1013-1024.

Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, et al. 1999. The gene encoding ATPbinding cassette transporter 1 is mutated in Tangier disease, Nature genetics 22:347-351.

 Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. 2000. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771–1775.

Byun HW, Hong EM, Park SH, Koh DH, Choi MH, Jang HJ, Kae SH, Lee J. 2014. Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells. Hepatobiliary and pancreatic diseases. International Hepatobiliary & Pancreatic Diseases International 13:65-73.

Bryan A. Laffitte, Lily C. Chao, Jing Li, Robert Walczak, Sarah Hummasti, Sean B. Joseph, Antonio Castrillo, Damien C. Wilpitz. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue, PNAS 100:5419-5424.

Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. 2001. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 7:161-171.

Chuu CP, Lin HP. 2010. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Research 30:3643–3648.

Commerford SR, Vargas L, Dorfman SE. 2007. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Molecular Endocrinology 21(12):3002-12.

Costet P, Luo Y, Wang N, Tall AR. 2000. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. The Journal of Biological Chemistry 275:282.

Chen G, Liang G, Ou J, Goldstein JL, Brown MS. 2004. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proceedings of the National. Academy of Sciences of the United States of America 101:11245–11250.

Chen JY, Levy-Wilson B, Goodart S, Cooper AD. 2002. Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet. The Journal of  Biological  Chemistry 277:42588–42595.

Chen J, Zhang X, Kusumo H, Costa LG, Guizzetti M. 2012. Cholesterol efflux is differentially regulated in neurons and astrocytes: Implications for brain cholesterol homeostasis. Biochimica et Biophysica Acta 1831(2):263-275.

Chen M, Beaven S, Tontonoz P. 2005. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor. Journal of Lipid Research 46:2570–2579.

Chih-pin Chuu, Rou-Yu Chen, Richard A. Hiipakka, John M. Kokontis, Karen V. Warner, Jialing Xiang, and Shutsung Liao. 2007. The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochemical and Biophysical  Research Communications 357(2):341–346.

Chunyan Zhao, Karin Dahalman Wright. 2009. Liver X Receptors in cholesterol metabolism.  Journal of Endocrinology 204:233-240.

Chen X Wang L, Chen B,Yue J, Zhu G, Zhang C, Liu S, Yang H.  2016.  Down-Regulated : Expression of Liver X Receptor beta in Cortical Lesions of Patients with Focal Cortical Dysplasia.  Journal of Molecular Neuroscience 60(2):223-231.

Cao G, Liang Y, Broderick CL. 2003. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. The Journal of Biological Chemistry 278(2):1131–1136.

Chen M, Beaven SW, Tontonoz P.  2005. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor. The Journal of Lipid Research 46(12):2570–2579.

Dugail I, Le Lay S, Varret M, Le Liepvre X, Dagher G, Ferré P. 2003. New insights into how adipocytes sense their triglyceride stores. Is cholesterol a signal.  Hormone and Metabolic Research 35:204–210.

Desantis D, Tryon VV, Pollack JD.  1989. Metabolism of Mollicutes: the Embden-Meyerhof-Parnas Pathway and the Hexose Monophosphate Shunt, Journal of General Microbiology 135:683-691.

Dalen KT, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI.  2003. Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor . The Journal of Biological Chemistry 278(48):48283–48291.

Donkin JJ, Stukas S, Hirsch-Reinshagen V. 2010. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. The Journal of Biological Chemistry 285:34144-34154.

Courtaut F, Derangère V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rébé C.  2015. Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization. Oncotarget 6(29):26651–26662.

Gao M, Zeng Y, Guan Y, Hu Z, Zhong D, Shen X, Zhang L, Xu Z, Gong W, Zhang Y. 2012. Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells. The International Journal of Biochemistry and Cell Biology 44:2299-2307.

Grefhorst A, van Dijk TH, Hammer A. 2005. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. American Journal of Physiology Endocrinology and Metabolism 289(5): E829–E838.

Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F. 2002. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. The Journal of Biological Chemistry 277:34182–34190.

Geyeregger R, Zeyda M, Stulnig TM.  2006. Liver X receptors in cardiovascular and metabolic disease., Cellular and  Molecular Life Sciences 63(5):524-39.

Grempler R, Kienitz A, Werner T. 2004. Tumour necrosis factor alpha decreases glucose-6-phosphatase gene expression by activation of nuclear factor kappaB. Biochemical Journal 382:471-9.

Gerhard DS, Wagner L, Feingold EA. 2004. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Research 14(10B):2121–7.

Hozoji-Inada M, Munehira Y, Nagao K.  2011. LXRβ directly interacts with ABCA1 to promote HDL formation during acute cholesterol accumulation. The Journal of Biological Chemistry 286:20117-20124.

Hruz P, Mueckler M. 1999. Cysteine-scanning mutagenesis of transmembrane segment 7 of the GLUT1 glucose transporter. The Journal of  Biological Chemistry 274(51):36176–80.

Im SS, Osborne TF. 2011. Liver x receptors in atherosclerosis and inflammation. Circulation Research 108 (8):996–1001.

Illiana Meurs, Ruud Out, Theo Jc Van Berkel, Miranda van Eck. 2008. Role of the ABC transporters ABCA1 and ABCG1 in foam cell formation and atherosclerosis, Future Lipidology 3(6):675–687.

Jia Y, Cong R, Li R. 2012. Maternal low-protein diet induces gender-dependent changes in epigenetic regulation of the glucose-6-phosphatase gene in newborn piglet liver. The Journal of Nutrition 142:1659-65.

Jerzy BeĊ‚towski 2008. Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia. Department of pathophysiology medical university Poland 1755-5922.

Fukuchi J, Song C, Ko AL, Liao S. 2003.  Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids 68(7-8):685-91.

Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. 1996. An oxysterol signaling pathway mediated by the nuclear receptor LXR. Nature 383(6602):728–731.

Khan FA, Pandupuspitasari NS, Huang CJ, Hao X, Zhang S. 2016. SUMOylation: A link to future therapeutics. Current Issues in Molecular Biology 18:49-5.

Knut S. 2006. Liver X receptors: new drug targets to treat Type 2 diabetes?.  Future Lipidol. 1(2):181–189.  

Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone, OL, and Edwards, PA. 2005. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell metabolism 1:121-131.

Kim WD, Kay HY, Hwang SJ. 2011. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid Redox Signal 15:2135-2146.

Kase ET, Thoresen GH, Westerlund S, Hojlund K, Rustan AC, Gaster M. 2007. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50:2171-2180.

Knut Tomas Dalen, Stine marie Ulven, Krister Bamberg, Hilde Nebb. 2003. Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor α. Journal of Biological Chemistry 278:48283–48291.

Kelli S. Bramlett, Keith A. Houck, Kristen M. Borchert, Michele S. Dowless, Palaniappan Kulanthaivel, Youyan Zhang, Thomas P. Beyer, Robert Schmidt, Jeffrey S. Thomas, Laura F. Michael, Robert Barr, Chahrzad Montrose et al. 2003. A Natural Product Ligand of the Oxysterol Receptor, Liver X Receptor. The journal of  Pharmacology and experimental  Therapeutics 307:291–296.

Laffitte BA, Repa JJ, Joseph SB et al. 2002. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proceedings of the National Academy of Sciences USA 98(2):507–512.

Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H. 2001. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nature Genetics 27:79–83.

Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. The Journal of Biological Chemistry 272:3137–3140.

Lee YC, Huang HY, Chang CJ, Cheng CH, Chen YT. 2010. Mitochondrial GLUT10 facilitates dehydroascorbic acid import and protects cells against oxidative stress: mechanistic insight into arterial tortuosity syndrome. Human Molecular Genetics 19(19):3721–3733.

Laurencikiene J, Rydén M. 2012. Liver X receptor and fat metabolism. International Journal of Obesity 36(12):1494-502.

Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel, SB.  2001. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nature Genetics 27:79–83.

Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proceedings of the National Academy of Science 100:5419–5424.

Laffitte BA, Repa JJ, Joseph SB, et al. 2001.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proceedings of the National Academy of Science 98:507-512.

Mitro N, Mak PA, Vargas L. 2007. The nuclear receptor LXR is a glucose sensor. Nature 445(7124):219-223.

Mak PA, Laffi tte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, Tontonoz P, Edwards PA. 2002. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors a and b.The Journal of Biological Chemistry 277:31900-31908.

Mak PA, Kast-Woelbern HR, Anisfeld AM, Edwards PA. Identifi cation of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. Journal of Lipid Research 43:2037–2041, 277:31900–31908.

Korach-André M, Archer A, Barros RP, Parini P, Gustafsson JÅ. 2011. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating Brown Adipose Tissue activity. PNAS 108(1):403-408.

Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP. 1996. The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling. The Journal of Biological Chemistry 271(16):9189–92.

Makishima M, Lu TT, Xie W, Whitfi eld GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf  DJ. 2002. Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316.

A-González N1, Castrillo A. 2011. Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:982-994.

Nordstrom EA, Ryden M, Backlund EC, Dahlman I, Kaaman M, Blomqvist L. 2005. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 54:1726–1734.

Nancy Nader, Ng SS, Wang Y, Abel BS, Chrousos GP, Kino T. 2012. Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism, Plos One, 7(3):e26751.

Oram JF, Vaughan AM. 2000. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Current Opinion in Lipidology 11(3):253–60. 

Oram JF, Heinecke JW. 2005. ATPbinding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiological Reviews 85:1343-1372.

Out R, Hoekstra M, Habets K, Meurs I, de Waard V, Hildebrand RB, Wang Y, Chimini G, Kuiper J, Van Berkel TJ. 2008. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arteriosclerosis, Thrombosis, and Vascular Biology 28:258-264.

Out R, Hoekstra M, Hildebrand RB, Kruit JK, Meurs I. 2006. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arteriosclerosis Thrombosis and Vascular Biology 26:2295-2300.

Postic C, Dentin R, Girard J. 2004.  Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes and Metabolism 30:398-40.

Peet DJ, Turley SD, Ma W. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93:693-704.

Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson JA, Basso MD, Nambi P. 2006.  Liver X receptor (LXR)-beta regulation in LXR alpha-deficient mice: implications for therapeutic targeting. Molecular Pharmacology 70(4):1340-9.

Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V. LXR ligand lowers LDL cholesterol in primates is lipid neutral in hamster, and reduces atherosclerosis in mouse. The Journal of Lipid Research 50:2358–2370.

Ross R. 1999. Atherosclerosis – an inflamatory disease. The New England Journal of Medicine 340:115–126.

Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. 2002. Regulation of ATP binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. The Journal of Biological Chemistry 277:18793-18800.

Richard Lawn M, Wade DP, Couse TL,Wilcox JN.  2001. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arteriosclerosis. Thrombosis and Vascular Biology 21:378–385.  

Rongtau Zhu, Zhibing Ou, Xiongzhong Ruan, Jianping Gong. 2012. Role of liver X receptors in cholesterol efflux and inflammatory signaling (Review). Molecular Medicine Reports 5:895-900.  

Robinson-Rechavi, M.; Escriva Garcia, H.; Laudet, V. 2003. The nuclear receptor superfamily. Journal of Cell Science 116:585–586.

Ross SE, Erickson RL, Gerin I, DeRose PM, Bajnok L, Longo KA. 2002. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Molecular and Cell Biology 22:5989–5999.

Robert A. Rizza. 2010. Pathogenesis of Fasting and Postprandial Hyperglycemia in Type 2 Diabetes: Implications for Therapy, DIABETES  59:2697-2707.

Repa JJ, Turley SD, Lobaccaro JA et al. 2000. Regulation of absorption and ABC1- mediated efflux of cholesterol by RXR heterodimers. Science 289(5484):1524–1529

Vainio S, Jansen M, Koivusalo M, Róg T, Karttunen M, Vattulainen I, Ikonen E. 2005. Significance of Sterol Structural Specificity Desmosterol Cannot replace cholestrol in lipid Rafts. The Journal of Biological Chemistry 281:348-355.

Stulnig TM, Steffensen KR, Gao H. 2002. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Molecular Pharmacology 62:1299-305.

Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA. 2002. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51:2426-33.

Franckhauser S1, Muñoz S, Pujol A, Casellas A, Riu E, Otaegui P, Su B, Bosch F. 2002. Increased Fatty Acid Re-esterification by PEPCK Overexpression in Adipose Tissue Leads to Obesity Without Insulin Resistance. Diabetes 51.

Silverman BL, Metzger BE, Cho NH, Loeb CA. 1995. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes                      care 18:611-7.

Solt LA1, Kamenecka TM, Burris TP. 2012. LXR-mediated inhibition of CD4+ T helper cells. PLoS ONE 7 e46615.

Sim WC, Kim DG, Lee KJ, Choi YJ, Choi YJ, Shin KJ. 2015. Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver. Journal of Pharmacology and Experimental Therapeutics 355(3):362-9.

Schaefer EJ, Anderson DW, Zech LA. 1981. Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins. The Journal of Lipid Research 22:217–228.

Schwartz K, Lawn RM, Wade DP. 2000. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochemical and Biophysical Research Communication  274:794-802.

Tangirala RK, Bischoff ED, Joseph SB, Wagner BL et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 99:11896-11901.

Taylor JM, Allen AM, Graham A. 2014. Targeting mitochondrial 18 kDa translocatprotein (TSPO) regulates macrophage cholesterol efflux and lipid phenotype. Clinical science 127:603-613.

Thorens B, Mueckler M.  2010. Glucose transporters in the 21st Century. American Journal of Physiology Endocrinology and Metabolism 298(2):E141–E145.

T.Holyoak, Sarah M Sullivan. 2007. Structures of Rat Cytosolic PEPCK:  Insight into the Mechanism of Phosphorylation and Decarboxylation of Oxaloacetic Acid. Biochemistry 46(35):10078–10088.

Venkateswaran A, Laffitte BA, Joseph SB. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR. Proceedings of National Academy of Science 97(22):12097–12102.

Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA. 2006. The liver X-receptor a controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 44:368–378.

Gronemeyer H1, Gustafsson JA, Laudet V. 2002. Principles for modulation of the nuclear receptor super family Nature Reviews Drug Discovery 3:950–964.

Vaughan AM, Oram JF. 2005. ABCG1 redistributes cell cholesterol to domain removable by high density lipoprotein but not by lipid-depleted apolipoproteins. The Journal of biological chemistry 280:30150-30157.   

Temml V, Voss CV, Dirsch VM, Schuster D. 2014. Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening. Journal of Chemical Information and Modelling 24;54(2):367–371.

Wang DQ. 2007. Regulation of intestinal cholesterol absorption. Annual Reviews of  Physiology 69:221–248.

Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. 1995. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes and Development 9(9):1033–1045.

Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. 1995. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes & Development 9(9):1033–45.

Wan X, Huo Y, Johns M, Piper E, Mason JC, Carling D, Haskard DO, Boyle JJ. 2013. 5'-AMP-activated protein kinaseactivating transcription factor 1 cascade modulates human monoc y te-der i ved macrophages to atheroprotective functions in response to heme or metformin. Arteriosclerosis Thrombosis and Vascular Biology 33:2470-2480.

Wang MD, Kiss RS, Franklin V, McBride HM. 2007. Different intracellular trafficking of LDL- and acetylated LDL-derived cholesterol lead to distinct reverse cholesterol transport mechanisms. Journal of Lipid Research 48:633–645.

Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR. 2006. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arteriosclerosis Thrombosis  and Vascular Biology 26:1310–1316.

Wang Y, Kurdi-Haidar B, Oram JF. 2004. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. Journal of Lipid Research 45:972–980.

Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. 2005. Downregulation of liver X receptor-a in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. The Journal of Lipid Research 46:2377–2387.

Whitney KD, Watson MA, Goodwin B, Galardi CM. 2001. Liver X receptor (LXR) regulation of the LXRa gene in human macrophages.  Journal of  Biological Chemistry 276:43509–43515,

Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X. 2004. Liver X receptor-a mediates cholesterol effl ux in glomerular mesangial cells. American Journal of Physiology Renal Physiology 287:F886–F895.

World Health Organization. Fact sheet: obesity and overweight. Available online: (accessed on 5 October 2009).

Sheng X, Zhu X, Zhang Y, Cui G, Peng L, Lu X, Zang YQ. 2012. Rhein Protects against Obesity and Related Metabolic Disorders through Liver X Receptor-Mediated Uncoupling Protein 1 Upregulation in Brown Adipose Tissue. International Journal of Biological Sciences 8(10):1375–1384.

Yvan-Charvet L, Ranalletta M, Wang N, Han S. 2007. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. The Journal of clinical investigation 117:3900-3908.

Yu XH, Qian K, Jiang N, Zheng XL. 2014. ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clinica chimica acta; international journal of clinical chemistry 428:82-88.

Yu BL, Zhao SP, Hu JR. 2010. Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obesity Reviews 11:560–567.

Yang CD, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, Covey DF.  2006. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. Journal of Biological Chemistry 281:27816-27826.

Yamamoto T, Shimano H, Inoue N, Nakagawa Y. 2007. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. Journal of Biological Chemistry 282:11687–11695.

Yang C, McDonald JG, Patel A, Zhang Y, Umetani M, Xu F, Westover EJ, 2006. Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. Journal of Biological Chemistry 281:27816–27826.

Yang C, Yu L, Li W, Xu F, Cohen JC, Hobbs HH. 2004. Disruption of cholesterol homeostasis by plant sterols. Journal of Clinical Investigation 114.

Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Tomita S. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. Journal of Biological Chemistry  277(3):1705-11:813–822.

Yao XH, Chen L, Nyomba BL. 2006. Adult rats prenatally exposed to ethanol have increased gluconeogenesis and impaired insulin response of hepatic gluconeogenic genes.Journal of Applied Physiology 100:642-8.

Ou Z, Jiang M, Hu B, Huang Y, Xu M, Ren S, Li S, Liu S, Xie W, Huang M. 2011. Transcriptional Regulation of Human Hydroxysteroid Sulfotransferase SULT2A1 by LXRα. Drug Metabolism and Disposition 42(10):1684–1689.

Zuercher Zuercher WJ, Buckholz RG, Campobasso N, Collins JL, Galardi CM, Gampe RT, Hyatt SM, Merrihew SL, Moore JT, Oplinger JA, Reid PR, Spearing PK, Stanley TB, Stewart EL, Willson TM.  2010. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. Journal of Medicinal Chemistry 53:3412.

Manuscript Management System
Submit Article Subscribe Most Popular Articles Join as Reviewer Email Alerts Open Access